Daily Stock Analysis, APTO, Aptose Biosciences Inc, priceseries

Aptose Biosciences Inc. Daily Stock Analysis
Stock Information
Open
1.63
Close
1.62
High
1.65
Low
1.60
Previous Close
1.62
Daily Price Gain
0.00
YTD High
1.75
YTD High Date
Sep 12, 2017
YTD Low
0.78
YTD Low Date
Apr 26, 2017
YTD Price Change
0.27
YTD Gain
20.00%
52 Week High
3.20
52 Week High Date
Oct 12, 2016
52 Week Low
0.78
52 Week Low Date
Apr 26, 2017
52 Week Price Change
-0.61
52 Week Gain
-27.35%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 26. 2015
4.79
Mar 17. 2015
6.01
13 Trading Days
25.56%
Link
LONG
Apr 7. 2015
5.69
Apr 22. 2015
6.21
11 Trading Days
9.14%
Link
LONG
Oct 23. 2015
4.15
Nov 9. 2015
5.56
11 Trading Days
33.93%
Link
LONG
Jan 21. 2016
2.27
Feb 5. 2016
2.71
11 Trading Days
19.18%
Link
LONG
Dec 7. 2016
0.94
Dec 21. 2016
1.21
10 Trading Days
28.90%
Link
LONG
Mar 10. 2017
1.19
Mar 14. 2017
1.28
2 Trading Days
7.56%
Link
LONG
May 1. 2017
0.90
May 11. 2017
1.09
8 Trading Days
21.48%
Link
LONG
Jun 9. 2017
1.22
Jun 14. 2017
1.30
3 Trading Days
6.97%
Link
LONG
Sep 7. 2017
1.45
Sep 12. 2017
1.60
3 Trading Days
10.34%
Link
Company Information
Stock Symbol
APTO
Exchange
NasdaqCM
Company URL
http://http://www.aptose.com
Company Phone
647-479-9828
CEO
William G. Rice
Headquarters
Ontario
Business Address
5955 AIRPORT ROAD, SUITE 228, ., MISSISSAUGA, CANADA L4V 1R9
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0000882361
About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada.

Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, a small molecule that induces the transcription of the Krüppel-like factor 4 Gene in in vitro studies and in in vivo pharmacodynamic studies of human xenograft tumors in mice. The company's APTO-253 clinical program has completed Phase-I clinical trials for the treatment of various solid tumors; and Phase-Ib clinical trials for relapsed/refractory hematologic malignancies. It also develops APTO-500 program that focuses on discovering and developing small molecule inhibitors of maternal embryonic leucine zipper kinase; and is in a pre-clinical stage for oncology. It has a license agreement with Genentech Inc. to develop and sub-license a specified polypeptide; and collaboration agreement with Eli Lilly and Company to investigate a proprietary series of the company's compounds for veterinary medicine. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.